FibroBiologics, Inc. Annual Report Summary (Fiscal Year Ended December 31, 2025)

Unlock key insights into FibroBiologics, Inc.'s (FBLG) financial health and strategic direction. This summary offers a clear, concise overview of the company's performance and position for the fiscal year ending December 31, 2025, designed to inform investors.

1. Business Overview FibroBiologics, Inc. is a clinical-stage biotechnology company developing innovative fibroblast-based therapies for chronic diseases. The company primarily targets fibrotic conditions like idiopathic pulmonary fibrosis (IPF) and chronic kidney disease (CKD). Its lead candidate, FBLG-001, a proprietary fibroblast cell therapy, is currently in Phase 2 clinical trials for IPF. In 2025, the company focused its core operations on advancing this clinical program and expanding its research pipeline.

2. Financial Performance For the fiscal year ending December 31, 2025, FibroBiologics generated minimal revenue of approximately $1.2 million, primarily from research grants and collaboration agreements. The company reported a net loss of $38.5 million, reflecting substantial investment in research and development (R&D). R&D expenses increased by 25% year-over-year, reaching $32.1 million. This loss aligns with expectations for a clinical-stage biotechnology company prioritizing pipeline development. As of February 24, 2026, approximately 67.6 million shares of common stock were outstanding. The market value of common stock held by non-affiliates was estimated at $21.6 million as of June 30, 2025.

3. Management Discussion & Analysis (MD&A) Highlights Management's discussion and analysis provides a detailed explanation of FibroBiologics' financial condition, operational results, key achievements, and strategic direction.

Results of Operations: FibroBiologics' financial results for 2025 primarily reflect its status as a clinical-stage biotechnology company focused on pipeline development. The company generated approximately $1.2 million in revenue, mainly from research grants and collaboration agreements. It reported a net loss of $38.5 million, largely driven by significant investment in research and development (R&D). R&D expenses rose by 25% year-over-year to $32.1 million. This increase primarily stemmed from advancing the FBLG-001 program into Phase 2 clinical trials, which included higher clinical site costs, patient enrollment expenses, and manufacturing scale-up activities. Supply chain pressures for specialized reagents also contributed to higher R&D costs than anticipated. General and administrative expenses also supported the company's operational infrastructure, contributing to the net loss.

Liquidity and Capital Resources: As of December 31, 2025, FibroBiologics held $45.8 million in cash and cash equivalents. Based on current operating expenses and R&D spending, management estimates this cash position can fund operations for approximately 15 months. The company reported $15.0 million in total debt, primarily consisting of convertible notes due in 2027. A current ratio of 2.8 indicates healthy short-term liquidity. However, management recognizes the need for substantial additional capital to complete ongoing clinical programs, pursue regulatory approvals, and prepare for potential commercialization. The company plans to explore various financing options, such as equity offerings or strategic collaborations, within the next 12-18 months to secure necessary funding.

Operational Achievements and Strategic Focus: In 2025, FibroBiologics achieved several key operational milestones. The company successfully completed patient enrollment for the Phase 2a trial of FBLG-001 in IPF, with initial efficacy and safety data expected in Q2 2026. It also secured a new patent for its fibroblast isolation and expansion technology, strengthening its intellectual property portfolio. A slight delay in regulatory feedback for a planned expansion into a new indication posed a challenge. The company's strategic focus remains on rapidly and efficiently advancing FBLG-001 through clinical development, exploring its potential in additional fibrotic indications, and leveraging its fibroblast technology platform for new therapeutic targets. This strategy emphasizes strategic partnerships to reduce development risks and accelerate market access. The executive leadership team remained stable during 2025.

4. Key Risks As a "smaller reporting company" and an "emerging growth company," FibroBiologics benefits from certain regulatory exemptions but also carries a higher risk profile. Key risks include:

• Clinical Trial Success: The success of FBLG-001 and other pipeline candidates is uncertain. It depends on extensive clinical development, regulatory approval, and successful commercialization.
• Funding Needs: The company will require substantial additional capital to fund its operations, clinical trials, and potential commercialization efforts. Failure to secure adequate funding could significantly impact its ability to continue operations.
• Competition: FibroBiologics operates in a highly competitive biotechnology landscape. It faces competition from larger pharmaceutical companies and other biotechs with more advanced products or greater financial resources.
• Intellectual Property: The business relies heavily on patents and proprietary technology. Any challenges to its intellectual property could severely impact the company.
• Regulatory Environment: Changes in healthcare laws, regulations, or reimbursement policies could adversely affect the company's prospects.

5. Competitive Position FibroBiologics competes in the highly competitive fibrotic disease market. While larger players like Roche and Boehringer Ingelheim offer established therapies for IPF, FibroBiologics aims to differentiate FBLG-001 through its novel fibroblast-based mechanism of action. This approach targets underlying disease pathology rather than just symptom management. Its proprietary cell therapy platform serves as a key competitive advantage, even as it faces competition from other emerging cell and gene therapies.

6. Future Outlook For the upcoming fiscal year, FibroBiologics plans to announce top-line data from the FBLG-001 Phase 2a IPF trial by Q2 2026 and initiate a larger Phase 2b study by Q4 2026. The company also intends to expand its preclinical pipeline by identifying a second lead candidate for a new fibrotic indication. Management anticipates continued high R&D expenditures and expects to explore various financing options, including equity offerings or strategic collaborations, within the next 12-18 months to support its ambitious development goals.

7. Market Trends and Regulatory Changes The biotechnology sector continues to benefit from increasing demand for innovative therapies for chronic and rare diseases. However, evolving regulatory landscapes, particularly for cell and gene therapies, influence approval timelines and market access. Trends towards personalized medicine and regenerative therapies present significant opportunities for FibroBiologics, while increasing pressure on drug pricing and reimbursement remains a potential challenge.